OncoBrief

Concise oncology insights for clinicians.
Monthly key publications in thoracic oncology.
Curated by clinicians, for clinicians.

[OncoBrief @OncoBrief]

February’s #OncoBrief is live.

Lighter month for breakthroughs, but important questions on IO duration, circadian timing, EGFR brain mets, and pragmatic trial design.

https://t.co/NUgIxLsXER

#LungCancer #OncoBrie

[OncoBrief @OncoBrief]

January’s key thoracic oncology data is out.

Smarter sequencing, clearer negative trials, and refined perioperative IO — less escalation, more biology.

👉 January OncoBrief: https://t.co/ubMvAt9rHY

#LungCancer #ThoracicOncology

[OncoBrief @OncoBrief]

December thoracic oncology highlights:

Post-osimertinib ADCs, actionable MET resistance, perioperative chemo-IO, and integrated RT strategies.

Full issue: https://t.co/lTliNte049

#LungCancer #ClinicalTrials #Oncology

[OncoBrief @OncoBrief]

3,063 papers reviewed → 11 top studies.
October #OncoBrief is live.
Concise, clinical, and data-driven.

🔗https://t.co/XVSwyna4YJ

#Oncology #LungCancer #ADCs #Immunotherapy

[OncoBrief @OncoBrief]

ESMO 2025 | Thoracic Highlights
Key updates for clinicians ↓
• FLAURA2 – Osi+chemo ↑OS
• OptiTROP – TROP2 ADC > chemo post-TKI
• ALEX – Longest OS (ALK+)
• KN-671 – Durable 5y benefit
• HARMONi-6 – PFS gain (Sq-NSCLC)
🔗 https://t.co/zn0Gjd6Np0
#ESMO2025 #OncoBrief

[OncoBrief @OncoBrief]

🚨 ESMO 2025 — What to Watch in Lung Cancer

Highlights:
🔹 FLAURA 2 – Osimertinib + chemo (OS update)
🔹 KEYNOTE-671 – 5-yr peri-operative pembro
🔹 ELEVATE – Adjuvant ensartinib in ALK⁺ NSCLC

🔗 https://t.co/CW6JRLFMrf

#ESMO2025 #LungCancer